R
Rena Therapeutics
Creating new nucleic acid drugs realized by third platform technology
About Rena Therapeutics
Rena Therapeutics specializes in developing cutting-edge gene therapy solutions aimed at treating rare genetic disorders. The company operates in the biotechnology sector, focusing on advanced genome editing technologies to create effective treatments. Rena Therapeutics primarily serves patients suffering from rare diseases, collaborating with healthcare providers and research institutions to bring innovative therapies to market. The business model revolves around research and development, clinical trials, and eventual commercialization of gene therapies. Revenue is generated through partnerships, licensing agreements, and sales of approved therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Tokyo, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
DBJ Capital
Kanagawa Science Park
INCJ
Nippon Shokubai
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rena Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rena Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.